The pathophysiology of hypertension in systemic lupus erythematosus

被引:62
作者
Ryan, Michael J. [1 ]
机构
[1] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Jackson, MS 39216 USA
关键词
renal; inflammation; TUMOR-NECROSIS-FACTOR; C-REACTIVE PROTEIN; ANGIOTENSIN-II HYPERTENSION; FLOW-MEDIATED DILATION; CONVERTING ENZYME GENE; MURINE LUPUS; INSULIN-RESISTANCE; OXIDATIVE STRESS; PPAR-GAMMA; RENAL-DISEASE;
D O I
10.1152/ajpregu.90864.2008
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Ryan MJ. The pathophysiology of hypertension in systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 296: R1258-R1267, 2009. First published January 21, 2009; doi:10.1152/ajpregu.90864.2008.-Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disorder that predominantly affects women during their reproductive years. Although SLE can affect any organ system, the kidneys are prominently involved in the form of immune complex glomerulonephritis. In addition, in women with SLE, risk for the development of cardiovascular disease is dramatically increased. Hypertension is a major risk factor for cardiovascular disease and is highly prevalent in women with SLE. Nevertheless, there has been little exploration of the pathophysiological mechanisms that promote SLE hypertension. This review discusses the role of several mechanisms, with an emphasis on the kidney, in SLE hypertension. These mechanisms include the renin-angiotensin system, endothelin, oxidative stress, sex steroids, metabolic changes, peroxisome proliferator-activated receptor-gamma, and, perhaps most importantly, chronic inflammation and cytokines. Growing evidence suggests a link between chronic inflammation and hypertension. Therefore, elucidation of mechanisms that promote SLE hypertension may be of significant value not only for patients with SLE, but also for a better understanding of the basis for essential hypertension.
引用
收藏
页码:R1258 / R1267
页数:10
相关论文
共 149 条
[1]   CORRELATION BETWEEN SERUM LEVELS OF SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR AND DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
ADERKA, D ;
WYSENBEEK, A ;
ENGELMANN, H ;
COPE, AP ;
BRENNAN, F ;
MOLAD, Y ;
HORNIK, V ;
LEVO, Y ;
MAINI, RN ;
FELDMANN, M ;
WALLACH, D .
ARTHRITIS AND RHEUMATISM, 1993, 36 (08) :1111-1120
[2]  
Al-Herz A, 2003, J RHEUMATOL, V30, P493
[3]   Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension [J].
Alexander, BT ;
Cockrell, KL ;
Rinewalt, AN ;
Herrington, JN ;
Granger, JP .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2001, 280 (05) :R1388-R1392
[4]   Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary antiphospholipid syndrome [J].
Alves, JD ;
Ames, PRJ .
IMMUNOBIOLOGY, 2003, 207 (01) :23-28
[5]   Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. [J].
José Delgado Alves ;
Bruno Grima .
Current Rheumatology Reports, 2003, 5 (5) :383-390
[6]  
[Anonymous], 2007, HLTH US 2007 CHARTBO
[7]   Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus -: An open-label study [J].
Aringer, M ;
Graninger, WB ;
Steiner, GN ;
Smolen, JS .
ARTHRITIS AND RHEUMATISM, 2004, 50 (10) :3161-3169
[8]   Reproductive health in SLE [J].
Askanase, AD ;
Buyon, JP .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2002, 16 (02) :265-280
[9]   Impaired antioxidant status and decreased dietary intake of antioxidants in patients with systemic lupus erythematosus [J].
Bae, SC ;
Kim, SJ ;
Sung, MK .
RHEUMATOLOGY INTERNATIONAL, 2002, 22 (06) :238-243
[10]   Lack of flow mediated dilation and enhanced angiotensin II-induced constriction in skeletal muscle arterioles of lupus-prone autoimmune mice [J].
Bagi, Z. ;
Hamar, P. ;
Kardos, M. ;
Koller, A. .
LUPUS, 2006, 15 (06) :326-334